Innovative Strategies in Breast Cancer: AI Insights and Global Health Equity

Breast cancer has established itself as a leader in cancer research and treatment, particularly through its emphasis on early intervention strategies. The latest BCU conference focused on promoting women’s health via a multidisciplinary approach, building upon themes introduced at the 2024 conference. This commitment to integrating diverse medical disciplines underscores the importance of collaborative efforts in advancing patient outcomes and fostering innovation in breast cancer care.

AI and CT Scans for Assessing Biological Age

Current research is exploring the use of artificial intelligence (AI) to determine a patient’s biological age by analyzing data from CT scans – a concept that goes beyond chronological age. Perry J. PICKHARDT’s work leads him to consider the vast amount of data present in CT scans beyond signs of metastatic disease or treatment response-fat, muscle, calcium deposits, and the structure of organs such as the liver. While we don’t typically use all of this information during routine screenings, it holds significant potential for understanding a patient’s overall health and risk factors. The ultimate goal is to create a system that accurately stratifies patients into risk categories based on their unique metabolic profiles.

• What can incidental data bring to radiology?
• What cohort are you working with, and what parameters are you exploring?
• What is your main objective in combining all incidental data?

A New Era in Cancer Treatment: Recent Advances in Progress

Cancer treatment has always been a journey of evolution, with gradual improvements over time. However, the last couple of years have witnessed a remarkable shift. This isn’t just incremental improvement; we’re seeing “little spits of massive advance,” as Georgia DEMETRIOU describes it. The introduction of new therapies like CKD 4/6 inhibitors in the adjuvant setting exemplifies this leap forward. 2 drugs within this category have shown promising benefits, marking a turning point in treatment strategies. Due to its high profile, extensive research efforts, and strong patient advocacy, breast cancer serves as a model for other cancers, demonstrating the way forward in improving cancer care and outcomes.

• Why can breast cancer be a model for cancer research?
• What strategy to use to manage side effects in practice?
• What’s your take on new breast cancer treatments?

Bridging Cancer Care Gaps: AROME’s Mission in the Mediterranean

AROME is an association dedicated to supporting oncologists from the Mediterranean region for over a decade. Jospeph GLIGOROV is the co-founder and President of this organization. It has been shown recently that the incidence of advanced-stage cancers is more prevalent in LMIC (Low Middle Income Countries) compared to HIC (High Income Countries). This disparity indicates that treatment needs may not be identical across regions. While both rich and poor countries require essential treatments for curable diseases, LMIC often struggle with more metastatic diseases and limited access to expensive drugs beneficial in such case.

• What are the goals of AROME?
• Is there a list of essential medications for breast cancer?